Literature DB >> 23918832

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.

Takeru Wakatsuki1, Melissa J LaBonte, Pierre O Bohanes, Wu Zhang, Dongyun Yang, Mizutomo Azuma, Afsaneh Barzi, Yan Ning, Fotios Loupakis, Siamak Saadat, Nico Volz, Sebastian Stintzing, Rita El-Khoueiry, Wasaburo Koizumi, Masahiko Watanabe, Manish Shah, Justin Stebbing, Georgios Giamas, Heinz-Josef Lenz.   

Abstract

Lemur tyrosine kinase-3 (LMTK3) was recently identified as an estrogen receptor (ER)-α modulator related to endocrine therapy resistance, and its polymorphisms rs9989661 (T>C) T/T genotype and rs8108419 (G>A) G/G or A/G genotype predicted improved outcomes in breast cancer. Because different predominant ER distributions link to breast and gastric cancer and little is known of the prognostic role of LMTK3 in gastric cancer, this study was carried out to clarify the prognostic role of these polymorphisms in gastric cancer. One-hundred and sixty-nine Japanese and 137 U.S. patients with localized gastric adenocarcinoma were enrolled. Genomic DNA was extracted from blood or tissue, and all samples were analyzed by PCR-based direct DNA sequencing. Overall, these polymorphisms were not associated with survival in both cohorts. When gender was considered, in multivariate analysis, harboring rs9989661 T/T genotype was associated with disease-free survival [HR, 4.37; 95% confidence interval (CI), 2.08-9.18; P < 0.0001] and overall survival (OS; HR, 3.69; 95% CI, 1.65-8.24; P = 0.0014) in the Japanese males and time to recurrence (HR, 7.29; 95% CI, 1.07-49.80; P = 0.043) in the U.S. females. Meanwhile, harboring rs8108419 G/G genotype was associated with OS in the Japanese females (HR, 3.04; 95% CI, 1.08-8.56; P = 0.035) and the U.S. males (HR, 3.39; 95% CI, 1.31-8.80; P = 0.012). The prognostic role of these polymorphisms may be negative in gastric cancer. These findings suggest that the estrogen pathway may play a prognostic role in patients with gastric cancer but this may be dependent on the regional differences both in physiology and genetic alterations of gastric cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23918832      PMCID: PMC3810398          DOI: 10.1158/1535-7163.MCT-12-1134

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  52 in total

1.  A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

Authors:  Michele De Laurentiis; Grazia Arpino; Erminia Massarelli; Angela Ruggiero; Chiara Carlomagno; Fortunato Ciardiello; Giampaolo Tortora; Diego D'Agostino; Francesca Caputo; Giuseppe Cancello; Emilia Montagna; Luca Malorni; Luigia Zinno; Rossella Lauria; Angelo Raffaele Bianco; Sabino De Placido
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

2.  Racial/ethnic differences in sex hormone levels among postmenopausal women in the diabetes prevention program.

Authors:  Catherine Kim; Sherita Hill Golden; Kieren J Mather; Gail A Laughlin; Shengchun Kong; Bin Nan; Elizabeth Barrett-Connor; John F Randolph
Journal:  J Clin Endocrinol Metab       Date:  2012-08-09       Impact factor: 5.958

3.  Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.

Authors:  Meng-Min Liu; Chris Albanese; Carol M Anderson; Kristin Hilty; Paul Webb; Rosalie M Uht; Richard H Price; Richard G Pestell; Peter J Kushner
Journal:  J Biol Chem       Date:  2002-05-01       Impact factor: 5.157

4.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Authors:  M Tanner; M Hollmén; T T Junttila; A I Kapanen; S Tommola; Y Soini; H Helin; J Salo; H Joensuu; E Sihvo; K Elenius; J Isola
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

5.  Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma.

Authors:  Evangelos Chandanos; Carlos A Rubio; Mats Lindblad; Chongqi Jia; Apostolos V Tsolakis; Margaret Warner; Jan-Ake Gustafsson; Jesper Lagergren
Journal:  Gastric Cancer       Date:  2008-09-30       Impact factor: 7.370

6.  LMTK3 is implicated in endocrine resistance via multiple signaling pathways.

Authors:  J Stebbing; A Filipovic; L C Lit; K Blighe; A Grothey; Y Xu; Y Miki; L W Chow; R C Coombes; H Sasano; J A Shaw; G Giamas
Journal:  Oncogene       Date:  2012-08-06       Impact factor: 9.867

7.  No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan.

Authors:  Toshiaki Saeki; Muneo Sano; Yoshifumi Komoike; Hiroshi Sonoo; Hideo Honjyo; Kazunori Ochiai; Tadashi Kobayashi; Kenjiro Aogi; Nobuaki Sato; Seiji Sawai; Yasuo Miyoshi; Yoshio Miyoshi; Masahiro Takeuchi; Shigemitsu Takashima
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

8.  Influence of sex on the survival of patients with esophageal cancer.

Authors:  Pierre Bohanes; Dongyun Yang; Ruchika S Chhibar; Melissa J Labonte; Thomas Winder; Yan Ning; Armin Gerger; Léonor Benhaim; David Paez; Takeru Wakatsuki; Fotios Loupakis; Rita El-Khoueiry; Wu Zhang; Heinz-Josef Lenz
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

Review 9.  Genomic variants in exons and introns: identifying the splicing spoilers.

Authors:  Franco Pagani; Francisco E Baralle
Journal:  Nat Rev Genet       Date:  2004-05       Impact factor: 53.242

10.  REporting recommendations for tumour MARKer prognostic studies (REMARK).

Authors:  L M McShane; D G Altman; W Sauerbrei; S E Taube; M Gion; G M Clark
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

View more
  11 in total

1.  Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis.

Authors:  Hongbing Shi; Jun Wu; Mei Ji; Qi Zhou; Zhengguang Li; Xiao Zheng; Bing Xu; Haifeng Deng; Weiqing Zhao; Changping Wu; Jingting Jiang
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

2.  Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.

Authors:  Kexin Zhang; Lujun Chen; Haifeng Deng; Yongyi Zou; Juan Liu; Hongbing Shi; Bin Xu; Mingyang Lu; Chong Li; Jingting Jiang; Zhigang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer.

Authors:  Zhengguang Li; Jun Wu; Mei Ji; Liangrong Shi; Bin Xu; Jingting Jiang; Changping Wu
Journal:  Mol Clin Oncol       Date:  2014-06-03

4.  Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer.

Authors:  Zhaoguo Xu; Xiaoying Qi; Xiaoye Zhang; Li Yu
Journal:  Tumour Biol       Date:  2014-02-09

5.  Lemur tyrosine kinase-3 is a significant prognostic marker for patients with colorectal cancer.

Authors:  Hongbing Shi; Qing Li; Mei Ji; Jun Wu; Zhengguang Li; Xiao Zheng; Bin Xu; Lujun Chen; Xiaodong Li; Changqing Lu; Yan Tan; Changping Wu; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

6.  Molecular screening and docking analysis of LMTK3and AKT1 combined inhibitors.

Authors:  Loubna Allam; Ghrifi Fatima; Lakhlili Wiame; El Amri Hamid; Ibrahim Azeddine
Journal:  Bioinformation       Date:  2018-12-09

7.  The structure-function relationship of oncogenic LMTK3.

Authors:  Angeliki Ditsiou; Chiara Cilibrasi; Nikiana Simigdala; Athanasios Papakyriakou; Leanne Milton-Harris; Viviana Vella; Joanne E Nettleship; Jae Ho Lo; Shivani Soni; Goar Smbatyan; Panagiota Ntavelou; Teresa Gagliano; Maria Chiara Iachini; Sahir Khurshid; Thomas Simon; Lihong Zhou; Storm Hassell-Hart; Philip Carter; Laurence H Pearl; Robin L Owen; Raymond J Owens; S Mark Roe; Naomi E Chayen; Heinz-Josef Lenz; John Spencer; Chrisostomos Prodromou; Apostolos Klinakis; Justin Stebbing; Georgios Giamas
Journal:  Sci Adv       Date:  2020-11-13       Impact factor: 14.136

8.  Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue.

Authors:  Giorgia Marisi; Alessandro Passardi; Daniele Calistri; Wainer Zoli; Dino Amadori; Paola Ulivi
Journal:  Int J Mol Sci       Date:  2014-07-30       Impact factor: 5.923

9.  LMTK3 confers chemo-resistance in breast cancer.

Authors:  Justin Stebbing; Kalpit Shah; Lei Cheng Lit; Teresa Gagliano; Angeliki Ditsiou; Tingting Wang; Franz Wendler; Thomas Simon; Krisztina Sára Szabó; Timothy O'Hanlon; Michael Dean; April Camilla Roslani; Swee Hung Cheah; Soo-Chin Lee; Georgios Giamas
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

10.  AKT1 Polymorphism (rs10138227) and Risk of Colorectal Cancer in Moroccan Population: A Case Control Study.

Authors:  Loubna Allam; Housna Arrouchi; Fatima Ghrifi; Abdelhak El Khazraji; Ilham Kandoussi; Mohammed Amine Bendahou; Hamid El Amri; Mohamed El Absi; Azeddine Ibrahimi
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.